Matt Nelson, PhD
VP, Genetics and Genomics
Deerfield
Bending the drug R&D productivity curve with human genetics
For decades drug R&D productivity has followed a downward march in spite of tremendous improvements in the science of drug discovery, a tragic phenomenon coined Eroom’s law. We demonstrate how the expanding catalog of causal genetic insights into disease risk, severity, and progression should have an increasing impact discovery and development decisions, increasing probabilities of success and decreasing the costs to bring effective new therapies to patients.
